Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

(Re)defining biopharmaceutical

Nature Biotechnology volume 26, pages 743–751 (2008)Cite this article

Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rader, R.A. Biopharmaceutical Products in the US and European Markets, 6th ed., 2 vols., (BioPlan Associates, Rockville, MD, 2007). <http://www.biopharma.com/>

    Google Scholar 

  2. Rader, R.A. BioExecutive Intl., March, 60–65 (2005). <http://www.biopharma.com/BioExec_pt1.pdf>

  3. Rader, R.A. BioExecutive Intl., May, 42–49 (2005). <http://www.biopharma.com/BioExec_pt2.pdf>

  4. Walsh, G. & Jefferis, R. Nat. Biotechnol. 24, 1241–1252 (2006).

    Article  CAS  Google Scholar 

  5. Akers, M.J. BioProcess Intl. 4, 36–43 (2006).

    Google Scholar 

  6. Webster, C. et al. BioPharm Intl. July, 1 (2003).

  7. Copmann, T. et al. BioPharm Intl. March, 14–24 (2001).

  8. Scott, C. BioProcess Intl. 3, 80 (2005). <http://www.bioprocessintl.com/default.asp?page=article_display&docid=61200511&display=full/>

  9. Walsh, G. Eur. J. Pharm. Sci. 15, 135–138 (2002).

    Article  CAS  Google Scholar 

  10. Eby, R.J. et al. The Story of Prevnar (Pharmaceutical Research and Manufacturers Association, Washington, DC, 2008). <http://www.innovation.org/index.cfm/StoriesofInnovation/ InnovatorStories/The_Story_of_Prevnar/>

    Google Scholar 

  11. http://www.bio.org/speeches/pubs/er/biotechguide.pdf

  12. Ernst & Young . Beyond Borders: Ernst & Young Global Biotechnology Report 2007 (Ernst & Young, New York, 2007).

    Google Scholar 

  13. DeVol, R. et al. Biopharmaceutical Industry Contributions to State and US Economics (Milken Institute, Santa Monica, CA, USA, 2004). <http://www.milkeninstitute.org/pdf/biopharma_report.pdf>

    Google Scholar 

  14. <http://www.burrillandco.com/burrill/pr_1171302475/>

  15. Ernst & Young . Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (Ernst & Young, New York, 2000).

    Google Scholar 

  16. PhRMA. Introduction, 2005 Industry Profile (PhRMA, Washington, DC, 2006). <http://members.phrma.org/publications/publications//2005-03-17.1144.pdf>

  17. PhRMA. Annual Report 2006–2007: Biopharmaceutical Inspiration, (PhRMA, Washington, DC, 2007). <http://www.phrma.org/files/Annual_Report_2006_2007.pdf>

  18. Myshko, D. PharmaVOICE, October, 40–44 (2006).

  19. Frantz, S. Nat. Rev. Drug Discov. 5, 977–979 (2006).

    Article  CAS  Google Scholar 

  20. Simons, J. Fortune, 28 February 2006. <http://money.cnn.com/2006/02/27/news/companies/ pluggedin_fortune/index.htm/>

    Google Scholar 

  21. Anonymous. Seeking Alpha. 9 January 2007. <http://seekingalpha.com/article/23696-the-biotech-industry-30-years-of-failure-starting-with-genentech/>

  22. Chase, M. The Wall Street Journal, p. B1 (June 5, 2007). <http://online.wsj.com/public/article/SB118100806142024548-PFa4u2AiKfDHi25uT1jvHmdJZKA_20070612.html?mod=blogs>

    Google Scholar 

  23. Schoemaker, P. & Tomczyk, M.S. BioProcess Intl. 4, 64 (2006).

    Google Scholar 

  24. Rader, R.A. US BIOPHARMACOPEIA Registry of Biopharmaceutical Products (Biotechnology Information Institute, Rockville, MD, USA, 2007). <http://www.biopharmacopeia.com/>

    Google Scholar 

  25. German Association of Research-Based Pharmaceutical Companies (VFA). Biological/Biotechnological Generics Cannot Exist (VFA, Berlin, Germany, July 25, 2006). <http://www.vfa.de/vfa-bio_en/vb_press/vb_positionen_en/biosimilars.html>

  26. Miller, H.I. Trends Biotechnol. 5, 56–59 (2007).

    Article  Google Scholar 

  27. Rader, R.A. BioProcess Intl. 5, 28–39 (March 2007). <http://www.biopharma.com/whatsabiogeneric_pt1.pdf>

    Google Scholar 

  28. Rader, R.A. BioProcess Intl. 5, 20–27 (May 2007). <http://www.biopharma.com/whatsabiogeneric_pt2.pdf>

    Google Scholar 

  29. Katz, K.A. Br. J. Dermatol. 154, 809–812 (2006).

    Article  CAS  Google Scholar 

  30. <http://www.fda.gov/cber/faq.htm#3/>

Download references

Author information

Authors and Affiliations

  1. Ronald A. Rader is at the Biotechnology Information Institute, 1700 Rockville Pike, Suite 400, Rockville, Maryland 20852, USA. Further information related to this article is available at http://www.biopharmacopeia.com/. ron@biopharma.com ,

    Ronald A Rader

Authors
  1. Ronald A Rader
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rader, R. (Re)defining biopharmaceutical. Nat Biotechnol 26, 743–751 (2008). https://doi.org/10.1038/nbt0708-743

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0708-743

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing